Drug Trial Radar · NCT03735901
Enhancement of Stroke Rehabilitation With Levodopa
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
610
Actual
Start
Jun 14, 2019
Primary completion
Aug 27, 2024
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- University Hospital, Basel, SwitzerlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Swiss National Science Foundation
- First posted
- Nov 8, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trial investigates the benefits and harms of Levodopa /Carbidopa 100/25mg compared to placebo (given in addition to standardized rehabilitation based on the principles of motor learning) and whether there is an association with a patient-relevant enhancement of functional recovery in acute stroke patients. Study participants will be randomized 1:1.
Conditions
- Acute Stroke
- Stroke Rehabilitation
Interventions
IMP Levodopa 100mg/Carbidopa 25mgDrug
Study treatment will comprise 3 phases: 1. Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time; 2. full study treatment phase: from day 7 to day 34, 3 times per day (tid). 3. Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning.
Matching placeboDrug
Study treatment will comprise 3 phases: 1. Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time; 2. full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid). 3. Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fugl-Meyer-Motor Assessment Score (FMMA)Time frame: Assessed 3 months +/- 14 days after randomization
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Kantonsspital Aarau, Neurozentrum
Aarau, Switzerland
RehaClinic AG
Bad Zurzach, Switzerland
Kantonsspital Baden
Baden, Switzerland
Felix Platter Spital
Basel, Switzerland
Stroke-Center Universitätsspital Basel
Basel, Switzerland
Inselspital, Universitätsklinik für Neurologie
Bern, Switzerland
Kantonsspital Graubünden, Departement Innere Medizin / Neurologie
Chur, Switzerland
HFR Fribourg Hopital Cantonal, U. de Neurologie
Fribourg, Switzerland
Centre hospitalier universitaire vaudois, Service de Neurologie
Lausanne, Switzerland
HFR Meyriez-Murten, Clinique de Réhabilitation
Meyriez, Switzerland
Kantonsspital Münsterlingen
Münsterlingen, Switzerland
Reha Rheinfelden
Rheinfelden, Switzerland
Kantonsspital St.Gallen, Klinik für Neurologie
Sankt Gallen, Switzerland
Hôpital du Valais - Sion, Service de neurologie
Sion, Switzerland
Hôpital du Valais - Sion
Sion, Switzerland
Rehazentrum Valens, Klinik für Neurologie und Neurorehabilitation
Valens, Switzerland
Cereneo Schweiz AG
Vitznau, Switzerland
Zürcher RehaZentrum Wald
Wald, Switzerland
Rheinburg Klinik AG
Walzenhausen, Switzerland
Kantonsspital Winterthur
Winterthur, Switzerland
Rehaklinik Zihlschlacht
Zihlschlacht, Switzerland
Klinik Lengg AG
Zurich, Switzerland
Head Stroke Center Klinik Hirslanden
Zurich, Switzerland
Universitätsspital Zürich, Klinik für Neurologie
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.